mortality between facilities, and could also facilitate comparisons for other outcomes, including hospitalizations and costs. In the current environment of exceedingly high costs of ESRD care and nationwide efforts to control costs and maximize quality and outcomes in patients with chronic diseases, there is likely to be increasing interest in comparing facilities and even individual physicians on the basis of costs, quality, and outcomes of maintenance dialysis treatment. Accurate accounting for patient comorbidity—using tools such as the index developed by Liu et al.[7]—will be an essential component of these efforts.

DISCLOSURE
The author declared no competing interests.

REFERENCES
1. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; **40**: 373–383.
2. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; **45**: 613–619.
3. Davies SJ, Russell L, Bryan J et al. Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 1995; **26**: 353–361.
4. Khan IH, Catto GR, Edward N et al. Influence of coexisting disease on survival on renal-replacement therapy. Lancet 1993; **341**: 415–418.
5. Fried L, Bernardini J, Piraino B. Comparison of the Charlson Comorbidity Index and the Davies score as a predictor of outcomes in PD patients. Perit Dial Int 2003; **23**: 568–573.
6. van Manen JG, Korevaar JC, Dekker FW et al. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002; **40**: 82–89.
7. Liu J, Huang Z, Gilbertson DT et al. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010; **77**: 141–151.
8. Longenecker JC, Coresh J, Klag MJ et al. Validation of comorbid conditions on the end-stage renal disease Medical Evidence Report: the CHOICE Study. J Am Soc Nephrol 2000; **11**: 520–529.
9. Seliger SL, Weiss NS, Gillen DL et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; **61**: 297–304.
10. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; **360**: 1395–1407.
11. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; **353**: 238–248.
12. Wolfe RA, Ashby VB, Daugirdas JT et al. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000; **35**: 80–88.
13. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; **347**: 2010–2019.
14. Brookhart MA, Wang PS, Solomon DH et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; **17**: 268–275.
15. Bradbury BD, Brookhart MA, Winkelmayer WC et al. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis 2009; **54**: 554–560.
16. Technical Notes on the Standardized Mortality Ratio for the Dialysis Facility Reports. University of Michigan Kidney Epidemiology and Cost Center: Ann Arbor 2009.

Hydrogen: another gas with therapeutic potential

James F. George[1,2] and Anupam Agarwal[2,3]

Cardinal and colleagues describe the use of molecular hydrogen, the most abundant molecule in the universe, as a treatment for chronic allograft nephropathy (CAN) in a rat model of kidney transplantation. They demonstrate that the addition of hydrogen to the drinking water results in a decrease in the severity of CAN and increased graft survival, and they provide evidence that the mechanism of action could be due to a reduction in reactive oxygen species.

The list of therapeutic gases continues to grow. Previous studies have reported on the beneficial effects of gases such as nitric oxide (NO), carbon monoxide (CO), and, more recently, hydrogen sulfide (H_2S) in animal models of many diseases.[1–3] Inhaled NO is already in clinical use for the treatment of hypoxic respiratory failure and pulmonary hypertension, particularly in neonates, and additional uses of NO are being investigated in other settings of lung and cardiac diseases.[4] Convincing preclinical data have prompted the initiation of clinical trials involving the use of inhaled CO for delayed graft function in kidney transplant recipients and H_2S (using sodium sulfide) in patients undergoing coronary artery bypass surgery and in patients with impaired renal function (http://www.clinicaltrials.gov). Cardinal and colleagues[5] (this issue) now describe the use of yet another promising gaseous molecule, hydrogen (H_2), as a treatment for chronic allograft nephropathy (CAN) in a rat model of kidney transplantation. They nicely demonstrate that rat kidney allograft recipients fed water containing dissolved H_2 exhibited better graft survival, reduced incidence of CAN, lower levels of reactive oxygen species (ROS), and reduced activation of proinflammatory secretory and signaling pathways. CAN (also called interstitial fibrosis and tubular atrophy of unknown etiology (IF/TA)) remains one of the most vexing clinical entities for the renal transplant physician because it is remarkably recalcitrant to current treatment modalities and is a major cause of long-term graft loss.[6] Therefore, potential new approaches to the treatment of CAN such as the one described by Cardinal and colleagues[5] are of great interest.

Hydrogen is the first element in the periodic table and constitutes at least 90% of the observable universe.

[1]Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA; [2]Nephrology Research and Training Center, University of Alabama at Birmingham, Birmingham, Alabama, USA and [3]Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Correspondence: Anupam Agarwal, Division of Nephrology, THT 647, University of Alabama at Birmingham, 1900 University Boulevard, Birmingham, Alabama 35294, USA. E-mail: agarwal@uab.edu

Figure 1 | A schematic of reactive oxygen species generation in the mitochondria. Oxygen radicals are colored red. The potential sites for the neutralizing antioxidant effects of molecular hydrogen are shown. SOD-super oxide dismutase.

Robert Boyle (1671) was the first to produce hydrogen when he dissolved iron in diluted hydrochloric acid. This observation occurred long before it was actually discovered as a distinct gas in 1766 by Henry Cavendish, who originally called it 'inflammable air'; it was later named hydrogen (Greek *hydro*, 'water,' and *genes*, 'forming') by Lavoisier, the father of modern chemistry. On earth, free hydrogen is comparatively rare. The majority of hydrogen found on earth is in water and organic compounds. It is highly reactive in the presence of specific catalysts and/or heat. One of the more spectacular examples of its reactivity was shown in 1937 when the zeppelin *Hindenburg*, using hydrogen for lift, ignited and was destroyed in less than a minute in the ensuing conflagration. Therefore, the use of hydrogen as a therapeutic agent is not intuitively obvious. However, recent data have shown that hydrogen can behave as an antioxidant in biological systems because of its ability to reduce ROS.[7] ROS or free radicals, such as the superoxide anion (O_2^-), are generated through the leak of electrons to molecular oxygen in the mitochondria during the production of adenosine triphosphate by oxidative phosphorylation (Figure 1). In the normal state, mitochondria generate 2–3 nmol of superoxide anion per minute per milligram of protein,[8] resulting in the generation of the superoxide radical, hydrogen peroxide, and the highly toxic hydroxyl radical. These ROS can be safely reduced to water by superoxide dismutase, catalase, and glutathione peroxidase (Figure 1). During

ischemia–reperfusion injury, which inevitably occurs during organ transplantation, the balance between the generation of ROS and the mechanisms to detoxify them can be upset, resulting in the accumulation of ROS in the tissues, where they quickly react with lipids, proteins, and nucleic acids, causing disordered cellular functions.

The paper by Cardinal and colleagues[5] is based on the premise that oxidative stress, resulting from ischemia–reperfusion, is a common pathway of injury in the setting of transplantation and is therefore a significant contributor to the development of CAN. These findings are an extension of the elegant work of Ohsawa and colleagues, who were the first to demonstrate that inhalation of hydrogen gas was an effective antioxidant strategy in cultured neuronal cells and in a model of ischemia–reperfusion in the brain *in vivo*.[7] These authors also showed that hydrogen gas was capable of rapidly diffusing through membrane compartments, gaining ready access to the cytosol, mitochondria, and nucleus and reducing hydroxyl radicals (·OH; the strongest of oxidant species in living cells) but did not appear to compromise essential homeostatic mechanisms dependent on ROS.[7] Cardinal and colleagues[5] show that the administration of water containing dissolved hydrogen results in (1) a sustained increase in the levels of hydrogen in the kidney and serum, without any accumulation over time; (2) improved kidney allograft function over a 60-day follow-up

period; (3) a decrease in several markers of inflammation, including graft-infiltrating cells, proinflammatory cytokines, and mitogen-activated protein kinase activation; and (4) decreased levels of lipid peroxides and peroxynitrite in the tissues.

A variety of other gases, such as NO, CO, and H_2S, are considered poisonous in large amounts but, in smaller concentrations, have antioxidant properties or are involved in physiological functions. Given previous data, the interpretation that the beneficial effects of H_2 in a kidney transplant model are a result of antioxidant properties of the element is reasonable and likely. However, this may not be the sole explanation, and other as-yet undefined mechanisms may be involved. The presence of basal levels of H_2 indicates one or more endogenous sources, suggesting that it plays a physiological role. Precedent for this possibility can be easily found in other gas-generating systems. CO, which is endogenously generated during the degradation of heme by the heme oxygenase enzyme system,[9] was previously thought of exclusively as a toxic gas. It is now understood that CO, which also has beneficial effects in inflammation and oxidative stress, plays a physiological role and participates in several signaling pathways known to modulate inflammation.[2] In fact, several clinical trials using inhaled CO are ongoing, including one in kidney transplant recipients. NO has attracted the most attention because of its involvement in cardiovascular biology, blood pressure regulation, and kidney and vascular function. NO is generated from arginine by nitric oxide synthases and has a number of molecular targets, including guanylate cyclase (which CO also targets) and phosphodiesterases.[1] Therefore, given the increasing number of systems in which H_2 is being shown to mediate beneficial effects, and likely, in the future, deleterious ones as well, it is probable that involvement of H_2 in signaling pathways or other physiological functions will be found. The molecular gases, H_2, NO, and H_2S are much simpler in structure than many of the drugs in use today. Our knowledge of them will continue to expand, providing an exciting potential for an entirely new class of drugs in the treatment of kidney diseases and end-stage organ failure.

DISCLOSURE
The authors declared no competing interests.

REFERENCES
1. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. *Front Biosci* 2009; **14**: 1–18.
2. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. *Physiol Rev* 2006; **86**: 583–650.
3. Szabo C. Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Discov* 2007; **6**: 917–935.
4. Creagh-Brown BC, Griffiths MJ, Evans TW. Bench-to-bedside review: inhaled nitric oxide therapy in adults. *Crit Care* 2009; **13**: 221–230.
5. Cardinal JS, Zhan J, Wang Y *et al.* Oral hydrogen water prevents chronic allograft nephropathy in rats. *Kidney Int* 2010; **77**: 101–109.
6. Jevnikar AM, Mannon RB. Late kidney allograft loss: what we know about it, and what we can do about it. *Clin J Am Soc Nephrol* 2008; **3**(Suppl 2): S56–S67.
7. Ohsawa I, Ishikawa M, Takahashi K *et al.* Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med* 2007; **13**: 688–694.
8. Inoue M, Sato EF, Nishikawa M *et al.* Mitochondrial generation of reactive oxygen species and its role in aerobic life. *Curr Med Chem* 2003; **10**: 2495–2505.
9. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. *Kidney Int* 2006; **70**: 432–443.